PTCT241220P19000
- 0.00
- 0.000.00%
PTC Therapeutics Newsroom
J.P. Morgan Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Raises Target Price to $62
PTC Therapeutics Is Maintained at Equal-Weight by Barclays
PTC Therapeutics Analyst Ratings
Barclays Maintains PTC Therapeutics(PTCT.US) With Hold Rating, Raises Target Price to $45
Analysts Have Conflicting Sentiments on These Healthcare Companies: PTC Therapeutics (PTCT), Medtronic (MDT) and OptimizeRx (OPRX)
William Blair Maintains PTC Therapeutics(PTCT.US) With Buy Rating
PTC Therapeutics Gains Buy Rating Following FDA Approval of Groundbreaking Gene Therapy Kebilidi
Balancing Growth Prospects and Regulatory Challenges: A Hold Rating on PTC Therapeutics
PTC Therapeutics (PTCT) Receives a Hold From Barclays
A Quick Look at Today's Ratings for PTC Therapeutics(PTCT.US), With a Forecast Between $45 to $48
Morgan Stanley Maintains PTC Therapeutics(PTCT.US) With Hold Rating, Maintains Target Price $45
Baird Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Raises Target Price to $48
PTC Therapeutics Analyst Ratings
PTC Therapeutics: Strong Q3 Performance Amid Market and Regulatory Challenges, Holds Rating Amid Mixed Future Outlook
William Blair Maintains PTC Therapeutics(PTCT.US) With Buy Rating
William Blair Sticks to Its Buy Rating for PTC Therapeutics (PTCT)
Citi Maintains PTC Therapeutics(PTCT.US) With Sell Rating, Maintains Target Price $26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Nurix Therapeutics (NRIX) and PTC Therapeutics (PTCT)
BofA Securities Maintains PTC Therapeutics(PTCT.US) With Sell Rating, Cuts Target Price to $30
PTC Therapeutics Analyst Ratings